Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China
文献类型：期刊论文
| 作者 | Bingying Tang; Rumeng Liu; Shaofei Hu |
| 刊名 | BMC HEALTH SERVICES RESEARCH
 |
| 出版日期 | 2025 |
| 卷号 | 25期号:1页码:1-9 |
| ISSN号 | 1472-6963 |
| 英文摘要 | This study constitutes the first comprehensive economic evaluation of deucravacitinib versus apremilast for treating moderate-to-severe plaque psoriasis in China. Following the decision-tree This empirical evidence can be used to inform debates about the use of QALYs in drug price negotiations, reimbursement, and coverage policy making. |
| 语种 | 英语 |
| 源URL | [http://ir.yic.ac.cn/handle/133337/41355]  |
| 专题 | 烟台海岸带研究所_中科院烟台海岸带研究所知识产出 |
| 作者单位 | 中国科学院烟台海岸带研究所 |
| 推荐引用方式 GB/T 7714 | Bingying Tang,Rumeng Liu,Shaofei Hu. Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China[J]. BMC HEALTH SERVICES RESEARCH,2025,25(1):1-9. |
| APA | Bingying Tang,Rumeng Liu,&Shaofei Hu.(2025).Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China.BMC HEALTH SERVICES RESEARCH,25(1),1-9. |
| MLA | Bingying Tang,et al."Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China".BMC HEALTH SERVICES RESEARCH 25.1(2025):1-9. |
入库方式： OAI收割
来源：烟台海岸带研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。